- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07499856
Intradialytic Exercise Program Supported by Audiovisual Media Combined With Mindfulness (GREXID MIND)
March 25, 2026 updated by: Eva Segura Ortí, Cardenal Herrera University
Effectiveness of a Group Intradialytic Exercise Program Supported by Audiovisual Media Combined With Mindfulness (GREXID MIND)
Chronic kidney disease in hemodialysis leads to musculoskeletal and psychological complications that affect functionality and quality of life.
Intradialytic exercise and innovative technologies help reduce sedentary behaviour and improve health.
Additionally, mindfulness decreases stress, anxiety, depression, and pain, promoting well-being and treatment adherence.
There is a growing awareness of the need for more patient-centered approaches to address the substantial burden of physical and psychological symptoms that are not adequately managed by standard treatment strategies.
Intradialytic exercise programs have become an effective strategy to counteract sedentary behavior and improve the overall health of patients.
Implementing these programs through innovative technologies can facilitate their adoption and accessibility.
Complementarily, mindfulness-based interventions help reduce stress, anxiety, and depression, improve mood, decrease pain perception, and promote relaxation and rest, which positively impact health-related quality of life and treatment adherence.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Valencia
-
Valencia, Valencia, Spain, 46115
- Universidad Cardenal Herrera CEU
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- ≥3 months on HD (3 weekly sessions of 4 hours)
Exclusion Criteria:
- lower-limb amputation;
- neurological, musculoskeletal or osteoarticular disorders;
- severe/unstable comorbidities (e.g., decompensated heart failure or diabetes, unstable angina, recent MI, uncontrolled hypertension, severe lung disease, acute infection);
- <3 months on HD;
- <2 sessions/week, or inability to understand assessments.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group Exercise intervention
This group will exercise intradialysis using a guided audiovisual program
|
This group will exercise with no added mindfulness intervention.
Group exercise intradialysis using audiovisual guide.
The comparison group (GE) will receive exercise + placebo music.
Each participant will complete 12 sessions.
Exercise will last 20-25 min; GE will listen to music.
Total session time: 40 min.
|
|
Experimental: GREX MIND Exercise and minfulness
This group will exercise (intradialysis exercise supported by audio visual guide) plus mindfulness program
|
The intervention group (GEM) will receive combined physical exercise + mindfulness.
Each participant will complete 12 sessions.
Exercise will last 20-25 min; GEM will add 20 min of mindfulness (guided meditation + virtual exploration).
Total session time: 40 min.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety assessment by hypotension episodes
Time Frame: From the start to the end of the intervention (4 weeks)
|
Exercise safety will be evaluated based on the total number of intradialysis group exercise sessions and their relationship with incidents or interruptions recorded in the progress sheets due to hypotension episodes.
|
From the start to the end of the intervention (4 weeks)
|
|
Safety assessment by fatigue
Time Frame: From start to the end of the intervention (4 weeks)
|
Exercise safety will be evaluated based on the total number of intradialysis group exercise sessions and their relationship with incidents or interruptions recorded in the progress sheets due to symptoms of fatigue.
|
From start to the end of the intervention (4 weeks)
|
|
Safety assessment by muscle cramps
Time Frame: From the start to the end of the intervention (4 weeks)
|
Exercise safety will be evaluated based on the total number of intradialysis group exercise sessions and their relationship with incidents or interruptions recorded in the progress sheets due to muscle cramps.
|
From the start to the end of the intervention (4 weeks)
|
|
Recruitment rate Assessment
Time Frame: Start of the study
|
Number of participants recruited/number of potential participants identified x 100
|
Start of the study
|
|
Retention rate
Time Frame: From start to the end of the intervention (4 weeks)
|
Number of participants completing the intervention/number of participants recruited x 100
|
From start to the end of the intervention (4 weeks)
|
|
Adherence rate
Time Frame: From start to the end of the intervention (4 weeks)
|
number of sessions completed/number of planned sessions x 100
|
From start to the end of the intervention (4 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle strength assessment Handgrip
Time Frame: It will be tested before and after the 4 weeks of intervention
|
It will use a Jamar® Approved Hydraulic Hand Dynamometer.
The participant will be seated in a chair with their back straight and the arm flexed at 90°.
The test will be repeated three times for each hand (3-5 seconds), with rest periods between repetitions to avoid muscle fatigue.
The cut-off points for loss of muscle strength will be set greater than or equal to 27 kg for men and greater than or equal to 16 kg for women, based on values defined by Mathiowetz et al. and included in the European clinical nutrition guidelines as a phenotypic criterion for disease-related malnutrition.
|
It will be tested before and after the 4 weeks of intervention
|
|
Lower limb muscle strength
Time Frame: From start to the end of the intervention (4 weeks)
|
Lower limb muscle strength assessments using digital handheld dynamometry will be performed during hemodialysis, using the Lafayette Instrument Company MMT handheld dynamometer, model 01165 (Lafayette, IN, USA), with Newtons as the unit of measurement.
The following lower extremity muscle groups will be evaluated: hip flexors and hip abductors.
In accordance with the guidelines for lower limb strength assessment, tests will be conducted with subjects in a supine position and in the triple flexion position of the lower extremities.For hip flexion, the dynamometer will be positioned on the anterior aspect of the thigh, two centimeters above the upper border of the patella.
The subject will perform a hip flexion movement while the evaluator, positioned at the subject's side, applies an opposing force of equal intensity.
To evaluate the hip abductors, the dynamometer will be positioned on the lateral aspect of the thigh, two centimeters above the knee joint line.
|
From start to the end of the intervention (4 weeks)
|
|
Anxiety and Depression
Time Frame: From start to the end of the intervention (4 weeks)
|
To evaluate Anxiety and Depression using Hospital Anxiety and Depression Scale (HADS).
The Hospital Anxiety and Depression Scale (HADS) is a widely used 14-item self-report questionnaire that screens for clinically significant anxiety and depression in both hospital patients with physical illnesses and the general population.
It's split into two subscales (7 items each) for anxiety (HADS-A) and depression (HADS-D), using a 4-point Likert scale to assess current feelings, crucially avoiding somatic symptoms like fatigue to better detect mood issues in physically ill people.
Scores range from 0 to 21 for anxiety and for depression, with higher scores indicating worst depression and anxiety
|
From start to the end of the intervention (4 weeks)
|
|
Human Activity Profile
Time Frame: From start to the end of the intervention (4 weeks)
|
The HAP consist of 94 questions addressing different domains of daily activity and participation, with three possible answers for each item: 'still doing,' 'stopped doing,' or 'never did.'
For each item, the participant will have to choose one of these responses.
Based on each answer, two scores will be calculated: the Maximal Activity Score (MAS), which corresponds to the activity with the highest effort demand that the volunteer 'still performs'; and the Adjusted Activity Score (AAS), which will be calculated by subtracting the number of items the subject 'has stopped doing' below the MAS value from the MAS itself.
The AAS will provide the value of activity that the subject has ceased to perform compared to what they were doing before.
|
From start to the end of the intervention (4 weeks)
|
|
Perceived Stress
Time Frame: From start to the end of the intervention (4 weeks)
|
To evaluate Perceived Stress taking Perceived Stress Scale (PSS).The Perceived Stress Scale (PSS) is a widely used self-report questionnaire designed to measure how stressful people find their lives, assessing the degree to which situations are appraised as unpredictable, uncontrollable, and overwhelming over the past month.
The scale is rated from 0 to 56, higher score indicates higher stress.
|
From start to the end of the intervention (4 weeks)
|
|
Perceptions from professionals and participants
Time Frame: From start to the end of the intervention (4 weeks)
|
To evaluate the perceptions from professionals and participants taking Self-Compassion Scale.
The Self-Compassion Scale is a widely used psychological questionnaire, that measures how individuals treat themselves during times of suffering or failure, assessing core components like Self-Kindness vs. Self-Judgment, Common Humanity vs. Isolation, and Mindfulness vs. Over-identification.
It helps gauge your capacity to offer yourself warmth, understanding, and connection, promoting better mental well-being, resilience, and personal growth by recognizing struggles as universal rather than isolating
|
From start to the end of the intervention (4 weeks)
|
|
Screening for sarcopenia risk
Time Frame: From start to the end of the intervention (4 weeks)
|
Screening for sarcopenia risk will be performed using the SARC-F questionnaire, which consists of five self-reported questions based on the subjects' perception of their limitations regarding strength, walking ability, rising from a chair, climbing stairs, and their history and number of falls.
Each item will be scored from 0 to 2, where 0 = no difficulty, 1 = some difficulty, and 2 = great difficulty, or if the subject uses devices or cannot perform the task without personal assistance.
The total SARC-F score can range from 0 to 10, and subjects with a score ≥ 4 points will be considered at risk of sarcopenia, in accordance with the recommendations of the European consensus on sarcopenia
|
From start to the end of the intervention (4 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eva Segura Ortí, Professor, Cardenal Herrera University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Handheld Dynamometry Testing During Dialysis: Intrarater and Interrater Reliability Study
- Doi: 10.23736/s1973-9087.21.06694-6
- doi: 10.1093/ckj/sfaa268
- DOI: 10.1111/sms.13304
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 14, 2026
Primary Completion (Estimated)
April 14, 2026
Study Completion (Estimated)
April 30, 2026
Study Registration Dates
First Submitted
March 20, 2026
First Submitted That Met QC Criteria
March 25, 2026
First Posted (Actual)
March 30, 2026
Study Record Updates
Last Update Posted (Actual)
March 30, 2026
Last Update Submitted That Met QC Criteria
March 25, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Behavior
- Renal Insufficiency, Chronic
- Motor Activity
Other Study ID Numbers
- CEEI25/733
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease (Stages 3b-5)
-
Maimónides Biomedical Research Institute of CórdobaCompletedChronic Kidney Disease (Stages 3b-5)Spain
-
Taipei Medical University HospitalCompletedMild Cognitive Disorder | Chronic Kidney Disease (Stages 3b-5)Taiwan
-
Kaiser PermanenteTerminatedChronic Kidney Disease Stages 3-5United States
-
Peking University First HospitalRecruitingChronic Kidney Disease (Stages 3b-5)China
-
Prince of Wales Hospital, Shatin, Hong KongTuen Mun Hospital; The Queen Elizabeth Hospital; Princess Margaret Hospital,... and other collaboratorsNot yet recruitingAtrial Fibrillation | Dialysis | Left Atrial Appendage Occlusion | Stroke Prevention in Patients With Atrial Fibrillation | Chronic Kidney Disease (Stages 3b-5) | End Stage Kidney FailureHong Kong
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
Manchester University NHS Foundation TrustNot yet recruitingChronic Kidney Disease 5D | Chronic Kidney Disease (Stages 4 and 5)United Kingdom
-
Ace Cells Lab LimitedRecruitingDiabetic Nephropathies | Chronic Kidney Disease | Microalbuminuria | Hypertensive Nephropathy | Chronc Kidney Disease Stage 5 | Auto Immune Disorders | Chronic Kidney Disease (Stages 4 and 5) | Chronic Kidney Disease (Stage 3-4)Egypt
-
Universidad de GranadaNot yet recruitingChronic Kidney Disease (Stages 4 and 5)
-
Centre Hospitalier Universitaire de la RéunionNot yet recruitingChronic Kidney Disease (Stages 4 and 5) | Chronic Kidney Disease (Stage 3-4)France
Clinical Trials on GREX
-
The Hong Kong Polytechnic UniversityRecruitingChronic Low Back PainHong Kong